IART INTEGRA LIFESCIENCES HOLDIN...

Nasdaq integralife.com


$ 15.66 $ 0.14 (0.9 %)    

Wednesday, 29-Oct-2025 13:31:38 EDT
QQQ $ 634.61 $ -0.94 (-0.15 %)
DIA $ 478.51 $ -0.08 (-0.02 %)
SPY $ 687.78 $ -0.98 (-0.14 %)
TLT $ 91.59 $ -0.29 (-0.32 %)
GLD $ 367.22 $ -2.43 (-0.66 %)
$ 15.56
$ 15.39
$ 15.65 x 82
$ 15.67 x 100
$ 15.38 - $ 15.75
$ 11.06 - $ 27.13
834,007
na
1.21B
$ 1.21
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2025 06-30-2025 10-Q
2 05-05-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 11-04-2024 09-30-2024 10-Q
5 07-29-2024 06-30-2024 10-Q
6 05-06-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 10-25-2023 09-30-2023 10-Q
9 07-27-2023 06-30-2023 10-Q
10 04-26-2023 03-31-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 10-26-2022 09-30-2022 10-Q
13 07-27-2022 06-30-2022 10-Q
14 04-27-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-02-2021 09-30-2021 10-Q
17 07-29-2021 06-30-2021 10-Q
18 04-29-2021 03-31-2021 10-Q
19 02-23-2021 12-31-2020 10-K
20 10-29-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-21-2020 12-31-2019 10-K
24 10-25-2019 09-30-2019 10-Q
25 07-25-2019 06-30-2019 10-Q
26 04-29-2019 03-31-2019 10-Q
27 02-26-2019 12-31-2018 10-K
28 11-01-2018 09-30-2018 10-Q
29 07-26-2018 06-30-2018 10-Q
30 04-26-2018 03-31-2018 10-Q
31 03-01-2018 12-31-2017 10-K
32 10-26-2017 09-30-2017 10-Q
33 07-26-2017 06-30-2017 10-Q
34 04-26-2017 03-31-2017 10-Q
35 02-23-2017 12-31-2016 10-K
36 10-28-2016 09-30-2016 10-Q
37 07-28-2016 06-30-2016 10-Q
38 04-27-2016 03-31-2016 10-Q
39 02-26-2016 12-31-2015 10-K
40 11-04-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 truist-securities-maintains-hold-on-integra-lifesciences-raises-price-target-to-15

Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:IART) with a Hold and raises the price tar...

 integra-lifesciences-to-showcase-new-neurosurgical-innovations-at-cns-2025-in-los-angeles-october-11-through-15-2025

- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, is pleased to announce ...

 integra-lifesciences-affirms-fy2025-adj-eps-guidance-of-219-229-vs-224-est-narrows-fy2025-sales-guidance-from-1650b-1715b-to-1655b-1680b-vs-1667b-est

Integra Lifesciences (NASDAQ:IART) affirms FY2025 Adj EPS guidance from $2.19-$2.29 to $2.19-$2.29 vs $2.24 analyst estimate. N...

 integra-lifesciences-sees-q3-adj-eps-040-045-vs-058-est-sees-sales-410000m-420000m-vs-418831m-est

Integra Lifesciences (NASDAQ:IART) is looking for Q3 Adj EPS of $0.40-$0.45 vs $0.58 analyst estimate. sees sales of $410.000 m...

 integra-lifesciences-q2-adj-eps-045-beats-043-estimate-sales-415605m-beat-395067m-estimate

Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of ...

 fda-announces-applicator-recall-integra-lifesciences-removes-micromyst-applicators-due-to-potential-sterility-concerns

https://www.fda.gov/medical-devices/medical-device-recalls/applicator-recall-integra-lifesciences-removes-micromyst-applicators...

 cranial-drill-recall-integra-lifesciences-recalls-codman-disposable-perforators-due-to-risk-of-device-disassembly---fda

https://www.fda.gov/medical-devices/medical-device-recalls/cranial-drill-recall-integra-lifesciences-recalls-codman-disposable-...

 jmp-securities-maintains-market-outperform-on-integra-lifesciences-lowers-price-target-to-25

JMP Securities analyst David Turkaly maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the pr...

 jp-morgan-maintains-underweight-on-integra-lifesciences-lowers-price-target-to-12

JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and lowers the price target ...

 wells-fargo-maintains-equal-weight-on-integra-lifesciences-lowers-price-target-to-13

Wells Fargo analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target ...

 integra-lifesciences-lowers-fy2025-adj-eps-guidance-from-241-251-to-219-229-vs-246-est-affirms-fy2025-sales-guidance-of-165b-172b-vs-168b-est

Integra Lifesciences (NASDAQ:IART) lowers FY2025 Adj EPS guidance from $2.41-$2.51 to $2.19-$2.29 vs $2.46 analyst estimate. Af...

 integra-lifesciences-sees-q2-adj-eps-040-045-vs-057-est-sees-sales-390000m-400000m-vs-41704m-est

Integra Lifesciences (NASDAQ:IART) is looking for Q2 Adj EPS of $0.40-$0.45 vs $0.57 analyst estimate. sees sales of $390.000 m...

 integra-lifesciences-q1-adj-eps-041-misses-043-estimate-sales-38265m-beat-38117m-estimate

Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.41 per share which missed the analyst consensus estimate o...

 truist-securities-maintains-hold-on-integra-lifesciences-lowers-price-target-to-19

Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price tar...

 argus-research-upgrades-integra-lifesciences-to-buy

Argus Research analyst David Toung upgrades Integra Lifesciences (NASDAQ:IART) from Hold to Buy.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION